Impact of Achieving ASDAS LDA on Disease Activity and Patient-Reported Outcome Measures Among Patients with Ankylosing Spondylitis Treated with Biologic DMARDs - ACR Meeting Abstracts

Background/Purpose: Although Ankylosing Spondylitis Disease Activity Score (ASDAS) low disease activity (LDA) is a common treatment target for disease control when managing AS, real-world research describing ASDAS LDA achievement among patients treated with biologic DMARDs (bDMARD) is limited. The aim of this study was to describe disease activity and patient-reported outcome measures (PROMs) among patients […]

Sex differences in the effectiveness of first-line tumour necrosis

Plenary Presentations - 2021 - International Journal of Rheumatic

Treat-to-target in axial spondyloarthritis — what about physical

Canadian Rheumatology Association Meeting Quebec City Convention

PDF) Golimumab as the First-, Second-, or at Least Third-Line

Treating to Target(s) With Interleukin-17 Inhibitors - Charles W

Outcome measures used in psoriatic arthritis registries and

PDF) Multi-biomarker disease activity score as a predictor of

Disease Activity-Guided Stepwise Tapering but Not Discontinuation

The Ankylosing Spondylitis Disease Activity Score (ASDAS) is the